Compare DOW & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOW | IQV |
|---|---|---|
| Founded | 1897 | 1982 |
| Country | United States | United States |
| Employees | 35700 | 93000 |
| Industry | Major Chemicals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 43.1B |
| IPO Year | 2018 | 2013 |
| Metric | DOW | IQV |
|---|---|---|
| Price | $28.45 | $259.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 22 |
| Target Price | $33.63 | ★ $293.74 |
| AVG Volume (30 Days) | ★ 8.2M | 1.3M |
| Earning Date | 10-22-2026 | 10-27-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | ★ $39,968,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $9.24 | $6.78 |
| Revenue Next Year | N/A | $6.05 |
| P/E Ratio | ★ N/A | $160.80 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $20.89 | $154.50 |
| 52 Week High | $42.74 | $277.40 |
| Indicator | DOW | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 49.67 |
| Support Level | $26.70 | $252.53 |
| Resistance Level | $29.09 | $274.60 |
| Average True Range (ATR) | 0.69 | 7.41 |
| MACD | 0.12 | -2.00 |
| Stochastic Oscillator | 81.55 | 35.89 |
Dow is one of the largest plastics and chemicals producers in the world, ranking in the top five for upstream plastics production, such as polyethylene, or PE, and polypropylene, or PP. It has three reportable segments: packaging and specialty plastics (P&SP), industrial intermediates and infrastructure (II&I), and performance materials and coatings (PM&C). The company traces its roots to 1897 with the founding of the Dow Chemical Company. After a long history of chemical production, Dow strategically merged with DuPont in 2017. In 2019, Dow, DuPont, and Corteva were split to enhance operational focus on the assets of the chemical conglomerate.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.